Vol. 6 No. 1 (2026)
Reimbursement Reviews

Aripiprazole

decorative image of the issue cover

Published January 9, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses Aripiprazole, 2 mg to 15 mg per day administered orally
  • Indication under consideration for reimbursement: Adjunct to antidepressants for the treatment of major depressive disorder in adult patients who had an inadequate response to at least 1 prior antidepressant treatment.